CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: while there is optimism about new product developments and regulatory progress, there are notable concerns such as declining gross margins, increased operating expenses, and shipment timing issues. The Q&A session did not reveal any significant obstacles but highlighted uncertainties regarding revenue timing and clinical study timelines. These factors, coupled with stable revenue and no clear guidance changes, suggest a neutral stock price movement over the next two weeks.
Key Financial Performance
Revenue $2.8 million, consistent with prior year period. The number of capsules sold was modestly lower year-over-year, offset by a slight increase in ASP.
Gross Profit $1.3 million with a gross margin of 48% compared to 54% in the first quarter of 2025. The change in gross margin was primarily due to tariffs impacting cost of goods sold.
Operating Expenses $8.4 million, an increase of $1.5 million compared to the prior year period. This increase was driven primarily by continued investment in the pipeline, including development work related to the next-generation imaging sensor and clinical trial activities.
Cash and Cash Equivalents $17.9 million at the end of the quarter. The balance sheet was strengthened by a $14 million private placement in March, reflecting confidence in the strategy and providing additional flexibility for key priorities.
Capsules Shipped 6,229 CapsoCam Plus capsules compared to 6,447 in the prior year period, representing a year-over-year decrease of 3%, attributed to the timing of shipments now placed in the second quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CapsoCam Plus: Continued expansion in procedure volume and deeper engagement with existing accounts. AI-assisted reading capability for CapsoCam Plus is expected to launch shortly after midyear clearance.
CapsoCam Colon Gen 2: Development program remains on track with imaging and AI module expected in Q3 2026. Prioritization of Gen 2 aims to deliver a competitive and clinically differentiated product.
CapsoCam UGI program and pancreatic cancer initiative: Enrollment began in clinical study for noninvasive pancreatic disease screening, marking a significant milestone.
Expansion in GI networks: Secured key renewals with Indiana University Health Systems, Providence Health Systems, and Gastro Health, reinforcing long-term customer relationships.
International market expansion: Dedicated team in Germany and distributor partnerships in high-potential markets.
AI Highlights: AI-assisted reading capability branded as AI Highlights aims to streamline review time and enhance workflow efficiency.
Sales infrastructure: Leverage existing sales infrastructure for cross-selling opportunities without significant incremental headcount.
AI-enabled diagnostic system: Focus on advancing a fully integrated AI-enabled diagnostic system to improve gastrointestinal disease detection.
Financial strategy: Strengthened balance sheet with $14 million private placement to support product innovation, clinical development, and commercial expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue and Sales Performance: Revenue remained consistent year-over-year at $2.8 million, but there was a 3% decrease in the number of capsules sold, attributed to shipment timing. This could indicate potential challenges in maintaining sales growth.
Gross Margin Decline: Gross margin decreased from 54% in Q1 2025 to 48% in Q1 2026, primarily due to tariffs impacting cost of goods sold. This poses a financial risk to profitability.
Operating Expenses: Operating expenses increased by $1.5 million year-over-year, driven by investments in pipeline development and clinical trials. This could strain financial resources if revenue growth does not offset these costs.
Regulatory Approval and Product Launch: The company is awaiting 510(k) clearance for its AI-assisted reading capability, expected midyear. Delays or issues in regulatory approval could impact the planned commercial launch and revenue projections.
Supply Chain and Tariffs: Tariffs have increased the cost of goods sold, affecting gross margins. This indicates potential supply chain vulnerabilities and cost pressures.
Market Competition: The company is prioritizing the development of its second-generation CapsoCam Colon to remain competitive. Delays or failure to deliver a clinically differentiated product could impact market positioning.
Clinical Trials and Pipeline Development: Ongoing clinical trials and pipeline investments, such as the pancreatic cancer program, represent long-term opportunities but also carry risks related to clinical success and financial sustainability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AI-assisted reading capability for CapsoCam Plus: The company expects regulatory clearance for its AI-assisted reading capability around midyear 2026, with a commercial launch shortly thereafter. This capability is designed to streamline review time and enhance workflow efficiency for physicians.
CapsoCam Colon Gen 2: Development program remains on track with imaging and AI module expected in Q3 2026. The company believes prioritizing the second generation positions them for a competitive and clinically differentiated product.
Pancreatic cancer screening program: Enrollment has begun in a clinical study to establish diagnostic criteria for a noninvasive screening approach for pancreatic disease. This is considered a longer-term opportunity with significant potential impact.
Revenue expectations for 2026: The company expects second quarter revenue to be higher than the first quarter and revenue in the second half of the year to exceed the first half, driven by pipeline momentum, customer engagement, and the anticipated AI module launch.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the status of the application for the AI-assisted reading feature with the FDA?
A:The company has addressed the FDA's requests during previous interactions and is now waiting for a meeting in the next few weeks. There are no significant obstacles to their knowledge.
Q:What is the size and timeline for the pancreatic cancer clinical study?
A:The study plans to enroll 120 patients with high-grade dysplasia or pancreatic cancer, with an additional 20 patients to account for dropouts, totaling 140. Additionally, 120 healthy reference images will be used, making a total of 240 subjects. The timeline for enrollment is not specified, but it is expected to be shorter than the colon study.
Q:What are the expectations for operating expenses (OpEx) throughout the year?
A:OpEx will see continued investment in the colon study through Q3, with a decline expected in Q4 as the study concludes. Other expenses are expected to remain stable with nominal growth to support the business.
Q:What factors impacted the first quarter revenue number?
A:The first quarter revenue was impacted by timing, with some larger orders falling into April instead of March. There was no price increase, but a shift in the sales mix to higher-priced regions contributed to higher ASPs. Deductible resets and other market factors were not significant contributors.
Q:How does the research and development (R&D) spending for the full year compare to 2025?
A:R&D spending for the full year is expected to be similar to 2025 levels, with significant investment in the colon study continuing through Q3.
Q:Review of Unclear Management Responses
A:Management avoided providing a specific timeline for the pancreatic cancer clinical study enrollment, citing the constraints of being a public company. Additionally, while discussing the first quarter revenue, they did not elaborate on the impact of deductible resets or other market factors, leaving some aspects of the revenue explanation vague.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Highlights
AI application
AI highlight
AI system
ASP patient
CPT code
CapsoCam practice
CapsoCams disease
CapsoVision detection
Colon clearance
Colon development
Form SEC
Gastro Health
Gen position
Gen program
Health Systems
Health engagement
Health value
Highlights friend
Indiana University
Instructions afternoon
Officer Vice
Officer patient
Physicians potential
Plus clearance
Plus closing
Providence Health
Sales today
Systems Gastro
Systems Providence
University Health
account addition
account reliance
network Indiana
provider
renewal GI
trend
utilization
volume
CV Transcript
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals: while there is optimism about new product developments and regulatory progress, there are notable concerns such as declining gross margins, increased operating expenses, and shipment timing issues. The Q&A session did not reveal any significant obstacles but highlighted uncertainties regarding revenue timing and clinical study timelines. These factors, coupled with stable revenue and no clear guidance changes, suggest a neutral stock price movement over the next two weeks.
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call highlights steady revenue growth and strong adoption of CapsoCam Plus, but concerns about financial sustainability and product development risks temper the positive outlook. The Q&A session reveals ongoing product development with potential delays due to summer vacations. Despite raising additional funds, high operating expenses and unclear timelines for FDA submissions are concerns. The overall sentiment is neutral, as strong financial metrics are offset by uncertainties in product development and financial sustainability.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
